Watari Ryuji, Kakiki Motoharu, Yamasaki Chihiro, Ishida Yuji, Tateno Chise, Kuroda Yukie, Ishida Seiichi, Kusano Kazutomi
Drug Metabolism and Pharmacokinetics Tsukuba, Global Drug Metabolism and Pharmacokinetics, Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd.
Department of Genomics-Based Drug Discovery, Graduate School of Comprehensive Human Sciences, University of Tsukuba.
Biol Pharm Bull. 2019;42(3):348-353. doi: 10.1248/bpb.b18-00582.
In drug discovery, hepatocytes have been widely utilized as in vitro tools for predicting the in vivo hepatic clearance (CL) of drug candidates. However, conventional hepatocyte models do not always reproduce in vivo physiological function, and CYP activities in particular decrease quite rapidly during culture. Furthermore, conventional in vitro assays have limitations in their ability to predict hepatic CL of metabolically stable drug candidates. In order to accurately predict hepatic CL of candidate drugs, a new method of culturing hepatocytes that activates their functional properties, including CYP activities, is in high demand. In the previous study, we established a novel long-term culture method for PXB-cells using a collagen vitrigel membrane (CVM) chamber, which can maintain CYP activity and liver specific functions at high levels for several weeks. In this study, the vitrigel culture method was applied to predictions of hepatic CL for 22 CYP typical substrates with low to middle CL, and the prediction accuracy by this method was assessed by comparing CL data between predicted (in vitro intrinsic CL using the dispersion model) and observed (in vivo clinical data) values. The results of this study showed that in vitro CL values for approximately 60% (13/22) and 80% (18/22) of the compounds were predicted within a 2- and 3-fold difference with in vivo CL, respectively. These results suggest that the new culture method using the CVM chamber and PXB-cells is a promising in vitro system for predicting human hepatic CL with high accuracy for CYP substrates, including metabolically stable drug candidates.
在药物研发中,肝细胞已被广泛用作体外工具,用于预测候选药物的体内肝脏清除率(CL)。然而,传统的肝细胞模型并不总能重现体内生理功能,尤其是细胞色素P450(CYP)活性在培养过程中会迅速下降。此外,传统的体外试验在预测代谢稳定的候选药物的肝脏CL方面存在局限性。为了准确预测候选药物的肝脏CL,迫切需要一种新的肝细胞培养方法来激活其功能特性,包括CYP活性。在先前的研究中,我们使用胶原玻璃膜(CVM)腔室建立了一种用于PXB细胞的新型长期培养方法,该方法可以在数周内将CYP活性和肝脏特异性功能维持在较高水平。在本研究中,将玻璃膜培养方法应用于预测22种低至中等CL的CYP典型底物的肝脏CL,并通过比较预测值(使用分散模型的体外内在CL)和观察值(体内临床数据)之间的CL数据来评估该方法的预测准确性。本研究结果表明,分别约60%(13/22)和80%(18/22)的化合物的体外CL值与体内CL的差异在2倍和3倍以内。这些结果表明,使用CVM腔室和PXB细胞的新培养方法是一种很有前景的体外系统,可用于高精度预测包括代谢稳定的候选药物在内的CYP底物的人体肝脏CL。